查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1692191

细胞重编程市场 - 全球产业规模、份额、趋势、机会和预测，按技术、应用、最终用户、地区和竞争细分，2020-2030 年预测

Cell Reprogramming Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Application, By End User, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球细胞重编程市场价值为 3.2545 亿美元，预计在预测期内将实现令人印象深刻的成长，到 2030 年的复合年增长率为 8.14%。细胞重编程已成为生物技术和再生医学领域的革命性领域。它有望将普通细胞转化为多能干细胞或直接将一种细胞类型转化为另一种细胞类型，为疾病建模、药物发现和再生疗法提供前所未有的机会。在技​​术进步、研究资金增加以及对创新医疗保健解决方案的需求不断增长的推动下，全球细胞重编程市场一直稳步增长。

市场概况
预测期 2026-2030
2024 年市场规模 3.2545 亿美元
2030 年市场规模 5.1635亿美元
2025-2030 年复合年增长率 8.14％
成长最快的领域 mRNA重编程
最大的市场 北美洲

细胞重编程涉及将成熟的、专门的细胞转化为更原始的状态，通常类似于胚胎干细胞。这个过程可以透过各种技术实现，其中最着名的是诱导多能干细胞 (iPSC) 重编程和直接谱系转换。 iPSC 重编程使科学家能够提取成体细胞并重拨其发育时钟，使其具有多能性并能够分化为各种细胞类型。相较之下，直接谱系转换跳过了多能阶段，直接将一种细胞类型转化为另一种细胞类型，例如将皮肤细胞转化为神经元。

全球细胞重编程市场受到多种多样的应用所推动。细胞重编程有可能彻底改变再生医学，因为它能够创造出患者特定的、有功能的移植细胞，从而降低排斥风险。研究人员可以利用多能干细胞创建针对特定疾病的细胞系，从而研究各种疾病的分子机制并筛选潜在的候选药物。细胞重编程在药物筛选和毒性测试中起着至关重要的作用，减少了动物测试的需要并加速了药物开发。多能干细胞可以从个别患者体内产生，从而可以製定个人化的疗法和治疗计划。

主要市场驱动因素

慢性病盛行率上升推动全球细胞重编程市场

主要市场挑战

技术复杂性

主要市场趋势

技术进步

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球细胞重编程市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依技术分类（基于仙台病毒、mRNA 重编程、其他）
    • 按应用（研究、治疗）
    • 按最终用户（研究和学术机构、生物技术和製药公司、医院和诊所、其他）
    • 按地区
    • 按公司划分（前五大市场参与者的份额，2024 年）
  • 市场地图
    • 依技术分类
    • 按应用
    • 按最终用户
    • 按地区

第六章：北美细胞重编程市场展望

  • 市场规模和预测
  • 市场占有率和预测

第 7 章：欧洲细胞重编程市场展望

  • 市场规模和预测
  • 市场占有率和预测

第 8 章：亚太地区细胞重编程市场展望

  • 市场规模和预测
  • 市场占有率和预测

第九章：南美细胞重编程市场展望

  • 市场规模和预测
  • 市场占有率和预测

第 10 章：中东和非洲细胞重编程市场展望

  • 市场规模和预测
  • 市场占有率和预测

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 合併与收购
  • 技术发布

第 13 章：竞争格局

  • Allele Biotechnology co. ltd.
  • ALSTEM, INC
  • Applied Biological Materials Inc.
  • Axol Bioscience Ltd.
  • Fujifilm Cellular Dynamics inc.
  • Lonza Group AG
  • Mogrify inc.
  • REPROCELL Inc.
  • Stemnovate Limited
  • Thermo Fisher Scientific Inc.

第 14 章：策略建议

第15章调查会社について・免责事项

简介目录
Product Code: 17395

The Global Cell Reprogramming Market was valued at USD 325.45 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.14% through 2030. Cell reprogramming has emerged as a revolutionary field in biotechnology and regenerative medicine. It holds the promise of transforming ordinary cells into pluripotent stem cells or directly converting one cell type into another, offering unprecedented opportunities for disease modeling, drug discovery, and regenerative therapies. The global cell reprogramming market has been steadily growing, driven by advancements in technology, increasing research funding, and a growing demand for innovative healthcare solutions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 325.45 Million
Market Size 2030USD 516.35 Million
CAGR 2025-20308.14%
Fastest Growing Segmentm RNA Reprogramming
Largest MarketNorth America

Cell reprogramming involves the conversion of mature, specialized cells into a more primitive state, often akin to embryonic stem cells. This process can be achieved through various techniques, with the most well-known being induced pluripotent stem cell (iPSC) reprogramming and direct lineage conversion. iPSC reprogramming allows scientists to take adult cells and rewind their developmental clock, making them pluripotent and capable of differentiating into various cell types. In contrast, direct lineage conversion skips the pluripotent stage, directly converting one cell type into another, such as turning skin cells into neurons.

The global cell reprogramming market is driven by a diverse range of applications. Cell reprogramming has the potential to revolutionize regenerative medicine by enabling the creation of patient-specific, functional cells for transplantation, thereby reducing the risk of rejection. Researchers can use pluripotent stem cell to create disease-specific cell lines, allowing them to study the molecular mechanisms of various diseases and screen potential drug candidates. Cell reprogramming plays a crucial role in drug screening and toxicity testing, reducing the need for animal testing and accelerating drug development. Pluripotent stem cell can be generated from individual patients, enabling the development of personalized therapies and treatment plans.

Key Market Drivers

Rising Prevalence of Chronic Diseases is Driving the Global Cell Reprogramming Market

The global healthcare landscape is witnessing a paradigm shift as chronic diseases continue to rise in prevalence. Diseases such as diabetes, cardiovascular disorders, neurodegenerative conditions, and cancer have become increasingly common, posing a significant challenge to healthcare systems worldwide. In response to this growing health crisis, the field of cell reprogramming is emerging as a promising frontier for addressing chronic diseases. The global cell reprogramming market is gaining momentum as researchers and biotechnology companies explore innovative ways to harness the regenerative potential of cells. For instance, the International Agency for Research on Cancer (IARC) projects that by 2040, the global cancer burden will rise to 27.5 million new cases and 16.3 million cancer-related deaths, largely due to population growth and aging. Additionally, an August 2022 article in the Radiation journal featured research by a Kindai University scientist in Japan exploring the optimal use of Radium-223 therapy for Metastatic Castration-Resistant Prostate Cancer. The study indicated that early administration of Ra-223 significantly improved overall survival (OS), highlighting potential advantages of using Ra-223 before novel hormonal or anticancer treatments.

Key Market Challenges

Technical Complexity

One of the primary challenges in the field of cell reprogramming is the technical complexity involved in generating high-quality iPSCs. Reprogramming adult cells into pluripotent stem cells is a delicate process that requires precise manipulation of cellular factors. Researchers must carefully select reprogramming methods, optimize culture conditions, and monitor cell differentiation to ensure the reliability and safety of iPSCs. This technical complexity not only demands considerable expertise but also makes the production of iPSCs time-consuming and costly.

Key Market Trends

Technological Advancements

The field of regenerative medicine has been revolutionized in recent years, thanks to significant advancements in cell reprogramming technology. Cell reprogramming, a process that involves resetting the identity of mature cells to a pluripotent state, has opened new avenues for the treatment of various diseases and the development of personalized medicine. As technological innovations continue to accelerate, the global cell reprogramming market is experiencing unprecedented growth. The advent of CRISPR-Cas9 technology has significantly enhanced the precision and efficiency of cell reprogramming. Researchers can now edit specific genes within cells, eliminating potential genetic mutations that may hinder the successful reprogramming process. This innovation has accelerated the production of high-quality iPSCs for various applications.

Automation systems and high-throughput screening platforms have streamlined the cell reprogramming process. This allows for the rapid generation of iPSCs in larger quantities, making them more accessible for research and clinical use. Automated systems also reduce the risk of contamination and human error, ensuring consistent and reliable results. Technological advancements in 3D bioprinting and the development of organoids have expanded the possibilities of cell reprogramming. These techniques enable the creation of complex, tissue-like structures from iPSCs, paving the way for more advanced disease modeling and drug testing. Artificial intelligence and machine learning algorithms have become integral in analyzing and interpreting large datasets generated from cell reprogramming experiments. These tools help identify novel factors and pathways involved in reprogramming, leading to more efficient and targeted approaches. Traditional methods of introducing reprogramming factors into cells often relied on viral vectors, which carried risks of genomic integration and mutagenesis. Non-viral delivery systems, such as synthetic RNA and protein-based approaches, have emerged as safer alternatives, improving the overall safety profile of cell reprogramming.

The global cell reprogramming market is witnessing remarkable growth, driven by these technological advancements and their applications. Pharmaceutical companies are increasingly investing in iPSC-based drug discovery and toxicity testing, while academic institutions are using iPSCs to study various diseases, including neurodegenerative disorders, heart disease, and cancer. Furthermore, the field of regenerative medicine is moving closer to the realization of personalized therapies. iPSCs derived from a patient's own cells can be reprogrammed and differentiated into specific cell types, offering the potential for individualized treatments and reduced risk of immune rejection.

Key Market Players

  • Allele Biotechnology co. ltd.
  • ALSTEM, INC
  • Applied Biological Materials Inc.
  • Axol Bioscience Ltd.
  • Fujifilm Cellular Dynamics inc.
  • Lonza Group AG
  • Mogrify inc.
  • REPROCELL Inc.
  • Stemnovate Limited
  • Thermo Fisher Scientific Inc

Report Scope:

In this report, the Global Cell Reprogramming Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Reprogramming Market, By Technology:

  • Sendai Virus-based
  • mRNA Reprogramming
  • Others

Cell Reprogramming Market, By Application:

  • Research
  • Therapeutic

Cell Reprogramming Market, By End user:

  • Research & Academic Institutes
  • Biotechnology & Pharmaceutical Companies
  • Hospitals & Clinics
  • Others

Cell Reprogramming Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Reprogramming Market.

Available Customizations:

Global Cell Reprogramming market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Reprogramming Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Sendai Virus-based, mRNA Reprogramming, Others)
    • 5.2.2. By Application (Research, Therapeutic)
    • 5.2.3. By End user (Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, Hospitals & Clinics, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (Shares of Top 5 Market Players, 2024)
  • 5.3. Market Map
    • 5.3.1. By Technology
    • 5.3.2. By Application
    • 5.3.3. By End user
    • 5.3.4. By Region

6. North America Cell Reprogramming Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Application
    • 6.2.3. By End user
    • 6.2.4. By Country
      • 6.2.4.1. United States Cell Reprogramming Market Outlook
        • 6.2.4.1.1. Market Size & Forecast
        • 6.2.4.1.1.1. By Value
        • 6.2.4.1.2. Market Share & Forecast
        • 6.2.4.1.2.1. By Technology
        • 6.2.4.1.2.2. By Application
        • 6.2.4.1.2.3. By End user
      • 6.2.4.2. Canada Cell Reprogramming Market Outlook
        • 6.2.4.2.1. Market Size & Forecast
        • 6.2.4.2.1.1. By Value
        • 6.2.4.2.2. Market Share & Forecast
        • 6.2.4.2.2.1. By Technology
        • 6.2.4.2.2.2. By Application
        • 6.2.4.2.2.3. By End user
      • 6.2.4.3. Mexico Cell Reprogramming Market Outlook
        • 6.2.4.3.1. Market Size & Forecast
        • 6.2.4.3.1.1. By Value
        • 6.2.4.3.2. Market Share & Forecast
        • 6.2.4.3.2.1. By Technology
        • 6.2.4.3.2.2. By Application
        • 6.2.4.3.2.3. By End user

7. Europe Cell Reprogramming Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Application
    • 7.2.3. By End user
    • 7.2.4. By Country
      • 7.2.4.1. France Cell Reprogramming Market Outlook
        • 7.2.4.1.1. Market Size & Forecast
        • 7.2.4.1.1.1. By Value
        • 7.2.4.1.2. Market Share & Forecast
        • 7.2.4.1.2.1. By Technology
        • 7.2.4.1.2.2. By Application
        • 7.2.4.1.2.3. By End user
      • 7.2.4.2. Germany Cell Reprogramming Market Outlook
        • 7.2.4.2.1. Market Size & Forecast
        • 7.2.4.2.1.1. By Value
        • 7.2.4.2.2. Market Share & Forecast
        • 7.2.4.2.2.1. By Technology
        • 7.2.4.2.2.2. By Application
        • 7.2.4.2.2.3. By End user
      • 7.2.4.3. United Kingdom Cell Reprogramming Market Outlook
        • 7.2.4.3.1. Market Size & Forecast
        • 7.2.4.3.1.1. By Value
        • 7.2.4.3.2. Market Share & Forecast
        • 7.2.4.3.2.1. By Technology
        • 7.2.4.3.2.2. By Application
        • 7.2.4.3.2.3. By End user
      • 7.2.4.4. Italy Cell Reprogramming Market Outlook
        • 7.2.4.4.1. Market Size & Forecast
        • 7.2.4.4.1.1. By Value
        • 7.2.4.4.2. Market Share & Forecast
        • 7.2.4.4.2.1. By Technology
        • 7.2.4.4.2.2. By Application
        • 7.2.4.4.2.3. By End user
      • 7.2.4.5. Spain Cell Reprogramming Market Outlook
        • 7.2.4.5.1. Market Size & Forecast
        • 7.2.4.5.1.1. By Value
        • 7.2.4.5.2. Market Share & Forecast
        • 7.2.4.5.2.1. By Technology
        • 7.2.4.5.2.2. By Application
        • 7.2.4.5.2.3. By End user

8. Asia Pacific Cell Reprogramming Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Application
    • 8.2.3. By End user
    • 8.2.4. By Country
      • 8.2.4.1. China Cell Reprogramming Market Outlook
        • 8.2.4.1.1. Market Size & Forecast
        • 8.2.4.1.1.1. By Value
        • 8.2.4.1.2. Market Share & Forecast
        • 8.2.4.1.2.1. By Technology
        • 8.2.4.1.2.2. By Application
        • 8.2.4.1.2.3. By Technology
      • 8.2.4.2. India Cell Reprogramming Market Outlook
        • 8.2.4.2.1. Market Size & Forecast
        • 8.2.4.2.1.1. By Value
        • 8.2.4.2.2. Market Share & Forecast
        • 8.2.4.2.2.1. By Technology
        • 8.2.4.2.2.2. By Application
        • 8.2.4.2.2.3. By End user
      • 8.2.4.3. South Korea Cell Reprogramming Market Outlook
        • 8.2.4.3.1. Market Size & Forecast
        • 8.2.4.3.1.1. By Value
        • 8.2.4.3.2. Market Share & Forecast
        • 8.2.4.3.2.1. By Technology
        • 8.2.4.3.2.2. By Application
        • 8.2.4.3.2.3. By End user
      • 8.2.4.4. Japan Cell Reprogramming Market Outlook
        • 8.2.4.4.1. Market Size & Forecast
        • 8.2.4.4.1.1. By Value
        • 8.2.4.4.2. Market Share & Forecast
        • 8.2.4.4.2.1. By Technology
        • 8.2.4.4.2.2. By Application
        • 8.2.4.4.2.3. By End user
      • 8.2.4.5. Australia Cell Reprogramming Market Outlook
        • 8.2.4.5.1. Market Size & Forecast
        • 8.2.4.5.1.1. By Value
        • 8.2.4.5.2. Market Share & Forecast
        • 8.2.4.5.2.1. By Technology
        • 8.2.4.5.2.2. By Application
        • 8.2.4.5.2.3. By End user

9. South America Cell Reprogramming Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Application
    • 9.2.3. By End user
    • 9.2.4. By Country
      • 9.2.4.1. Brazil Cell Reprogramming Market Outlook
        • 9.2.4.1.1. Market Size & Forecast
        • 9.2.4.1.1.1. By Value
        • 9.2.4.1.2. Market Share & Forecast
        • 9.2.4.1.2.1. By Technology
        • 9.2.4.1.2.2. By Application
        • 9.2.4.1.2.3. By End user
      • 9.2.4.2. Argentina Cell Reprogramming Market Outlook
        • 9.2.4.2.1. Market Size & Forecast
        • 9.2.4.2.1.1. By Value
        • 9.2.4.2.2. Market Share & Forecast
        • 9.2.4.2.2.1. By Technology
        • 9.2.4.2.2.2. By Application
        • 9.2.4.2.2.3. By End user
      • 9.2.4.3. Colombia Cell Reprogramming Market Outlook
        • 9.2.4.3.1. Market Size & Forecast
        • 9.2.4.3.1.1. By Value
        • 9.2.4.3.2. Market Share & Forecast
        • 9.2.4.3.2.1. By Technology
        • 9.2.4.3.2.2. By Application
        • 9.2.4.3.2.3. By End user

10. Middle East & Africa Cell Reprogramming Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Application
    • 10.2.3. By End user
    • 10.2.4. By Country
      • 10.2.4.1. South Africa Cell Reprogramming Market Outlook
        • 10.2.4.1.1. Market Size & Forecast
        • 10.2.4.1.1.1. By Value
        • 10.2.4.1.2. Market Share & Forecast
        • 10.2.4.1.2.1. By Technology
        • 10.2.4.1.2.2. By Application
        • 10.2.4.1.2.3. By End user
      • 10.2.4.2. Saudi Arabia Cell Reprogramming Market Outlook
        • 10.2.4.2.1. Market Size & Forecast
        • 10.2.4.2.1.1. By Value
        • 10.2.4.2.2. Market Share & Forecast
        • 10.2.4.2.2.1. By Technology
        • 10.2.4.2.2.2. By Application
        • 10.2.4.2.2.3. By End user
      • 10.2.4.3. UAE Cell Reprogramming Market Outlook
        • 10.2.4.3.1. Market Size & Forecast
        • 10.2.4.3.1.1. By Value
        • 10.2.4.3.2. Market Share & Forecast
        • 10.2.4.3.2.1. By Technology
        • 10.2.4.3.2.2. By Application
        • 10.2.4.3.2.3. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Technology Launches

13. Competitive Landscape

  • 13.1. Allele Biotechnology co. ltd.
  • 13.2. ALSTEM, INC
  • 13.3. Applied Biological Materials Inc.
  • 13.4. Axol Bioscience Ltd.
  • 13.5. Fujifilm Cellular Dynamics inc.
  • 13.6. Lonza Group AG
  • 13.7. Mogrify inc.
  • 13.8. REPROCELL Inc.
  • 13.9. Stemnovate Limited
  • 13.10.Thermo Fisher Scientific Inc.

14. Strategic Recommendations

15. About us & Disclaimer